| Mark Janorschke, CRNA | |
|
32791 Spunk Tree Cir, Avon, MN 56310-9626 | |
| (320) 493-8900 | |
| Not Available |
| Full Name | Mark Janorschke |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 26 Years |
| Location | 32791 Spunk Tree Cir, Avon, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720055171 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Glacial Ridge Hospital | Glenwood, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centracare Clinic | 2466363395 | 632 |
| Glacial Ridge Hospital District | 5294789194 | 44 |
| Deaconess Hospital Inc | 9032021431 | 308 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | The Duluth Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902563638 PECOS PAC ID: 2567374283 Enrollment ID: O20031103000229 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Centracare Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043212665 PECOS PAC ID: 2466363395 Enrollment ID: O20031105000293 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Unity Family Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326234006 PECOS PAC ID: 9830003516 Enrollment ID: O20031117000732 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Ccm Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720086028 PECOS PAC ID: 4284539453 Enrollment ID: O20031201000642 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Anesthesiology, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960798 PECOS PAC ID: 9335033034 Enrollment ID: O20040212000459 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Glacial Ridge Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255348223 PECOS PAC ID: 5294789194 Enrollment ID: O20050719000315 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Glacial Ridge Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538178520 PECOS PAC ID: 5294789194 Enrollment ID: O20061104000464 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1275872772 PECOS PAC ID: 3870739410 Enrollment ID: O20130426000215 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Entity Name | Centracare Health System-nr Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558600874 PECOS PAC ID: 3870739410 Enrollment ID: O20130515000683 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Janorschke, CRNA 32791 Spunk Tree Cir, Avon, MN 56310-9626 Ph: (320) 493-8900 | Mark Janorschke, CRNA 32791 Spunk Tree Cir, Avon, MN 56310-9626 Ph: (320) 493-8900 |
News Archive
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
One of the most common myths around older adults is that they are not sexually active. But a recent study conducted by researchers at Indiana University found that older men and women do maintain sexual relationships even into their 80s and beyond.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
A joint report from the Australian Institute of Health and Welfare (AIHW) and Cancer Australia has revealed that though non-melanoma skin cancer (NMSC) is by far the most common cancer diagnosed in Australia, just how common it is remains unclear.
› Verified 3 days ago